Eli Lilly (LLY) delivered another extraordinary quarter of growth, posting a 48% year-over-year sales increase despite a slower-than-expected launch for its oral obesity drug Foundayo. Lilly reported Foundayo sales of $98 million
More
The strategies that guided bio/pharma commercialization for decades are being overhauled simultaneously, driven by sweeping changes across pricing, technology, and patient care. A fragmenting pricing environment, next-generation therapies straining existing infrastructure, and
More
Legend Biotech has reported its first quarter of company-wide profitability in its history, sending shares of the CAR-T therapy maker climbing around 6%. The milestone came alongside second-quarter 2026 results that delivered
More
Fleet managers across the pharmaceutical and logistics sectors are facing mounting pressure to identify inefficiencies that standard reporting tools consistently fail to surface. Many organisations invest heavily in fleet management software, yet
More
Eli Lilly (LLY) has filed lawsuits against six US companies it accuses of selling illegal versions of its experimental weight-loss drug retatrutide. The Indianapolis drugmaker is targeting California’s Aesthetic Envy Cosmetic Centers
More
Snapchat has unveiled a new advertising format designed specifically for pharmaceutical marketers, making it easier to include required product disclosures within in-feed ads. The updated format allows pharma advertisers to attach product
More
Quanterix (QTRX) Names GE Healthcare And Exact Sciences Veteran Jim Gute As Chief Commercial Officer
Quanterix Corporation has appointed medtech veteran Jim Gute as its new chief commercial officer, signalling an ambitious push to accelerate commercial growth. Gute joins Quanterix from Exact Sciences, where he served as
More
Scholar Rock has removed Novo Nordisk’s Catalent manufacturing facility from its FDA submission for apitegromab, a spinal muscular atrophy treatment candidate, following a damaging inspection outcome. The troubled plant received an “Official
More
BridgeBio Pharma’s Attruby generated net product revenue of $222.4 million in Q2 2026, more than tripling the $71.5 million recorded in the same period a year ago. Total revenues climbed 120% to
More
WuXi AppTec has secured an early legal victory in its fight against the US Department of Defense over its controversial designation as a “Chinese military company.” Chief Judge James E. Boasberg of
More